Why your own cells do not mean zero risk

Category: Safety · Editorial Review: Updated 20 October 2026 · 3 minute read

Source and processing are different questions

Cells removed from the body may be concentrated, mixed, stored, transported, or expanded before being returned. These steps can change their properties and introduce handling risks. The collection itself may also involve a needle procedure or liposuction. A patient should therefore distinguish the biological origin of cells from the quality and clinical purpose of the finished preparation.

Discuss the whole pathway

Ask whether collection and treatment happen on the same day, whether the material leaves the clinic, and whether the preparation contains additives. Request the name of the processing facility and an explanation of the checks that occur before use. An autologous label is not proof that the preparation contains a defined stem cell population or that it treats your condition.

A useful decision boundary

Do not accept a waiver of discussion because the cells are your own. Ask for the same information about likely benefit, alternatives, collection complications, delivery complications, and follow-up that you would expect for any medical intervention. Keep a copy of the product and procedure description, especially if another doctor will care for you after travel.

Putting the discussion into practice

For example, a proposal may describe fat-derived material as both natural and highly concentrated. Those descriptions leave open the actual composition, processing method, and relevance to your diagnosis. Ask for a plain-language description that separates what is measured from what is assumed. Keep the collection consent separate from the administration consent so you can see the risks of both stages.

Questions to take to the consultation

Ask: What exactly happens between collection and return of my cells? Are they simply separated, expanded in culture, combined with another substance, or stored? What evidence supports this preparation rather than a differently processed one? Does the proposed treatment require any additional medicine? The useful response is a description of the actual process, not a general explanation of the benefits of autologous care. Ask to see the same terminology reflected in the treatment summary and consent.

Continue exploring

• Cell treatment safety: separate three kinds of risk
• Infection and cell-based procedures
• Contamination testing: what a certificate can and cannot tell you
• Prepare your consultation checklist

Sources & further reading

• FDA: Important patient information about regenerative medicine therapies

Read alongside your treating specialist’s advice. Clinical eligibility, exact products and treatment plans require individual assessment.